mizoribine has been researched along with transforming growth factor beta in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hyodo, N; Hyodo, T; Imakiire, T; Kikuchi, Y; Miura, S; Saigusa, T; Suzuki, S; Yamada, M | 1 |
| Arakawa, T; Doi, S; Ito, T; Kawai, T; Kohno, N; Masaki, T; Nakashima, A; Takahashi, S; Taniguchi, Y; Yorioka, N | 1 |
2 other study(ies) available for mizoribine and transforming growth factor beta
| Article | Year |
|---|---|
Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemokine CCL2; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosis; Glomerulosclerosis, Focal Segmental; Immunoenzyme Techniques; IMP Dehydrogenase; Macrophages; Male; Nephritis, Interstitial; Osteopontin; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleosides; RNA, Messenger; Sialoglycoproteins; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
Mizoribine suppresses the progression of experimental peritoneal fibrosis in a rat model.
Topics: Actins; Animals; Cell Movement; Chemokine CCL2; Chlorhexidine; Collagen Type III; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Fibrosis; Immunosuppressive Agents; Macrophages, Peritoneal; Peritoneal Diseases; Peritoneum; Rats; Rats, Wistar; Ribonucleosides; Transforming Growth Factor beta | 2009 |